Andersen Claus Y, Donnez Jacques, Ernst Erik, Gook Debbie, Pellicer Antonio, Von Wolff Michael, Suzuki Nao, Roux Christophe, Dolmans Marie-Madeleine
The Fertility Clinic, Copenhagen University Hospital Herlev, Herlev, Denmark; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Université Catholique de Louvain and Society for Research into Infertility (SRI), Brussels, Belgium.
Reprod Biomed Online. 2025 Jan;50(1):104442. doi: 10.1016/j.rbmo.2024.104442. Epub 2024 Sep 6.
This is a commentary to a paper recently published in RBMOnline by Macklon and De Vos, in which they argue for a discontinuation of ovarian tissue freezing for fertility preservation in women with breast cancer. Instead, they suggest the use of oocyte vitrification following ovarian stimulation as the preferred method of fertility preservation. This commentary presents nine separate arguments that should be considered in the context of ovarian tissue freezing and fertility preservation in girls and women. Collectively, the authors support ovarian tissue freezing going forward and suggest continuing this procedure for fertility preservation in women with breast cancer. Ovarian tissue freezing represents several advantages for patients and provides them with more options following treatment compared with oocyte vitrification.
这是对麦克隆(Macklon)和德沃斯(De Vos)最近发表在《生殖生物医学在线》(RBMOnline)上一篇论文的评论。在该论文中,他们主张停止对乳腺癌女性进行卵巢组织冷冻以保存生育能力。相反,他们建议在卵巢刺激后使用卵母细胞玻璃化作为首选的生育力保存方法。本评论提出了九个独立的论点,在女孩和女性卵巢组织冷冻及生育力保存的背景下应予以考虑。总体而言,作者支持继续进行卵巢组织冷冻,并建议继续对乳腺癌女性采用该方法来保存生育能力。与卵母细胞玻璃化相比,卵巢组织冷冻对患者具有诸多优势,且在治疗后能为她们提供更多选择。